Gary M. Owens, MD

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.

Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective

ByGary M. Owens, MD

March 31st 2014

As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.

Participating Faculty: Improving Transitions of Care for Patients With Thromboembolic Disease

ByGary M. Owens, MD,Claudia Fine, MSW, MPH,Darrell W. Harrington, MD,Alan K. Jacobson, MD, FACC,Geno J. Merli, MD,Edith Nutescu, PharmD, FCCP,Kenneth L. Schaecher, MD, FACP, CPC,Jacqueline Vance,

March 21st 2014

Improving Transitions of Care for Patients With Thromboembolic Disease

ByGary M. Owens, MD,Claudia Fine, MSW, MPH,Darrell W. Harrington, MD,Alan K. Jacobson, MD, FACC,Geno J. Merli, MD,Edith Nutescu, PharmD, FCCP,Kenneth L. Schaecher, MD, FACP, CPC,Jacqueline Vance,

March 20th 2014

Managed Care Aspects of Managing Multiple Sclerosis

ByGary M. Owens, MD

November 26th 2013

Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone

ByRobert Navarro, PharmD,Jeffrey D. Dunn, PharmD, MBA,Peter A. Lee, MD, PhD,Gary M. Owens, MD,Robert Rapaport, MD

November 24th 2013

The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases

ByGary M. Owens, MD

July 3rd 2013

Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.

Latest Updated Articles

Rethinking Heart Failure: Patient Classification and Treatment
Published: November 10th 2022 | Updated:
The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases
Published: July 3rd 2013 | Updated:
Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective
Published: March 31st 2014 | Updated:
Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for Payers
Published: March 31st 2014 | Updated:
New FDA Guidance on Biosimilars: Another Step Forward A Payer Perspective
Published: May 30th 2014 | Updated:
Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape
Published: January 1st 2015 | Updated:

Gary M. Owens, MD

Articles by Gary M. Owens, MD

Participating Faculty: Rethinking Heart Failure: Patient Classification and Treatment

Rethinking Heart Failure: Patient Classification and Treatment

The Spectrum of Progressive Fibrosing Interstitial Lung Disease: Clinical and Managed Care Considerations

Systemic Sclerosis With Associated Interstitial Lung Disease: Management Considerations and Future Directions

Idiopathic Pulmonary Fibrosis: Exploring the Clinical and Economic Implications of the Evolving Treatment Landscape

The Economic Burden and Managed Care Implications of Chronic Inflammatory Demyelinating Polyneuropathy

Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management

Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations-The New and Evolving Standards of Care

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape

Managed Care Implications in Managing Rheumatoid Arthritis

New FDA Guidance on Biosimilars: Another Step Forward A Payer Perspective

Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for Payers

Reflections on 2013-The First of the Breakthrough Therapies: A Payer Perspective

Participating Faculty: Improving Transitions of Care for Patients With Thromboembolic Disease

Improving Transitions of Care for Patients With Thromboembolic Disease

Managed Care Aspects of Managing Multiple Sclerosis

Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone

The Changing Management of Prostate Cancer-Radium 223 Dichloride (Xofigo) Targets Bone Metastases

Successful Aging in Men with BPH

Migraine in the Managed Care Environment

Clinician and Payer Issues in Managing Growth Hormone Deficiency

Latest Updated Articles

Trending on AJMC

FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis

Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD

Value-Based Care Interventions and Management of CKD Progression

FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC

NICU Nurses More Likely to Miss Tasks Due to Increased Workload